Home › Lung Diseases › Idaho › Boise
Lung Diseases clinical trials in Boise, ID
3 studies for Lung Diseases are looking for participants at sites in and around Boise (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RecruitingPhase 3
- Research Site, Boise
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
RecruitingPhase 3
- St. Luke's Humphreys Diabetes Center, Boise
- St. Luke's Children's, Boise
- St. Luke's Elks Children's Pavilion, Boise
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
RecruitingPhase 3
- Humphreys Diabetes Center, Boise
- St. Luke's Idaho Elks Children's Pavilion, Boise
About Lung Diseases
Lung diseases are disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. Find out more about prevention, living with lung diseases, and treatment.
More about Lung Diseases on MedlinePlus
Lung Diseases trials in other cities
- Houston, TX15 studies
- Boston, MA14 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Pittsburgh, PA11 studies
- Los Angeles, CA10 studies
- Columbus, OH10 studies
- Nashville, TN10 studies
- Dallas, TX10 studies
- Washington, DC10 studies
- Miami, FL10 studies
- Ann Arbor, MI10 studies
Other studies in Boise
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer11 studies
- Prostate Cancer8 studies
- Acute Myeloid Leukemia8 studies
- Colon Cancer7 studies
- Breast Cancer6 studies
- Melanoma6 studies
- Colorectal Cancer6 studies
- Respiratory Distress Syndrome6 studies
- Burkitt Lymphoma5 studies
- Traumatic Brain Injury4 studies
- Post-Concussion Syndrome4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.